Assess whether RWE can replace or only supplement an RCT (ea5fd4)

Situation

Advisory-committee question list that exposes a weak secondary endpoint arrived with a literature paper the 505(b)(2) package leans on getting retracted for 505(b)(2) development lead. That is a Pharma & Life Sciences Pharmacovigilance decision on RWE can replace or in a safety team sitting on a new disproportionate signal.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose RWE can replace / Only supplement an RCT using advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• 505(b)(2) development lead can defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge.
• 505(b)(2) development lead cannot defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint; Only supplement an RCT is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted.
• A literature paper the 505(b)(2) package leans on getting retracted never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close RWE can replace or.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move RWE can replace or for 505(b)(2) development lead.

Recommendation